TD 8954 (also known as TAK 954) is a selective serotonin 5-HT(4) receptor agonist. It is known a potential role for potent and efficacious 5-HT(4) receptor agonists in the treatment of Alzheimer's disease (AD). TD 8954 participated in phase I clinica...
l trials to study its potential role in the treatment of AD. However, this study was discontinued. In addition, TD 8954 is involved in phase II clinical trials to investigate its effect on gastrointestinal and colonic transit in diabetic or idiopathic gastroparesis participants and for the prophylaxis and treatment of postoperative gastrointestinal dysfunction in participants undergoing large- and small-bowel resection.
